Masimo Corp. (MASI) reported that its new customer, Brookdale University Hospital and Medical Center in Brooklyn, New York, has completed its system-wide conversion to Masimo SET pulse oximetry technology. Brookdale has also installed Masimo’s first-ever continuous and noninvasive hemoglobin monitoring (SpHb) technology in its select care settings. This allows clinicians to detect and treat chronic or acute anemia earlier, more effectively manage blood transfusions for their patients and identify internal bleeding quicker.
The Brookdale University Hospital and Medical Center is one of the largest voluntary nonprofit teaching hospitals in Brooklyn and a New York State Department of Health (DOH) designated Stroke Center. Masimo SET pulse oximetry enables clinicians to continuously and non-invasively measure multiple blood constituents that previously required invasive procedures. The multiple blood constituents measured are total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), etc.
Masimo SET pulse oximetry eliminates the need to draw blood and wait for results. This helps physicians to immediately detect and treat potentially life-threatening conditions.
Masimo develops, manufactures and markets a family of non-invasive blood monitoring systems that consist of a monitor, circuit board and sensors. The systems are primarily used to monitor blood oxygen saturation levels and protect against hypoxemia and hyperoxemia. Hypoxemia, low blood-oxygen levels, can cause brain damage and death. Hyperoxemia, high-blood oxygen levels, can permanently damage eyes and cause blindness.
Masimo is a leader in the pulse oximetry monitoring equipment market. The company’s closest competitors are Haemonetics Corp. (HAE) and Becton, Dickinson and Co. (BDX).
Read the full analyst report on “MASI”
Read the full analyst report on “HAE”
Read the full analyst report on “BDX”
Zacks Investment Research
